ScandiDos AB (SE:SDOS)

:SDOS

SDOS

ScandiDos AB

RESEARCH TOOLSreports

Want to see SE:SDOS full AI Analyst Report?

ScandiDos AB (SDOS) Price & Analysis

0 Followers

SDOS Stock Chart & Stats

kr1.15

kr0.01(0.67%)

At close: Mar 06 4:00 PM EST

kr1.15

kr0.01(0.67%)

Day’s Range― - ―

52-Week Rangekr0.81 - kr1.50

Previous CloseN/A

Volume16.76K

Average Volume (3M)69.69K

Market Cap

kr48.17M

Enterprise Valuekr41.75M

Total Cash (Recent Filing)kr4.36M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Sep 17, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding57,011,086

10 Day Avg. Volume66,689

30 Day Avg. Volume69,692

Financial Highlights & Ratios

PEG Ratio-1.02

Price to Book (P/B)1.34

Price to Sales (P/S)3.95

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetZero or negligible debt provides durable financial flexibility for a small medtech firm. It lowers default risk, supports continued R&D and regulatory compliance spend, and gives management time to fix operating issues without immediate refinancing pressure.

Historically High Gross MarginsHigh historical gross margins indicate the core QA products once had strong unit economics and pricing power. If product mix or costs are restored, those margins imply scalable profitability potential as sales recover and fixed costs are spread across greater volume.

Niche Radiotherapy QA Franchise With Recurring PotentialA focused QA product set in radiotherapy addresses a regulatory and safety-critical need, creating customer stickiness and high switching costs. Software licenses and service/support contracts can generate recurring revenue, stabilizing cash flows over the medium term.

Bears Say

Persistent Losses And Cash BurnSustained net losses and predominantly negative free cash flow erode equity and limit reinvestment capacity. Over 2–6 months this constrains product development, clinical support expansion, and marketing, raising execution risk unless cash consumption is arrested or new funding secured.

Stagnant To Declining Revenue TrendFlat-to-declining sales indicate difficulty growing market penetration or pricing power in a specialized niche. Weak top-line momentum impairs operating leverage, prevents fixed-cost absorption, and makes it harder to rebuild margins or fund recurring-revenue initiatives organically.

2026 Gross Profit DeteriorationNegative gross profit in 2026 suggests unit-level economics have broken, potentially from cost spikes, pricing pressures, or inventory/write-downs. This undermines the company's fundamental ability to generate profit from product sales and requires structural fixes to restore sustainable margins.

SDOS FAQ

What was ScandiDos AB’s price range in the past 12 months?

ScandiDos AB lowest stock price was kr0.81 and its highest was kr1.50 in the past 12 months.

What is ScandiDos AB’s market cap?

ScandiDos AB’s market cap is kr48.17M.

When is ScandiDos AB’s upcoming earnings report date?

ScandiDos AB’s upcoming earnings report date is Sep 17, 2026 which is in 91 days.

How were ScandiDos AB’s earnings last quarter?

ScandiDos AB released its earnings results on Jun 16, 2026. The company reported kr0.002 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.002.

Is ScandiDos AB overvalued?

According to Wall Street analysts ScandiDos AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ScandiDos AB pay dividends?

ScandiDos AB does not currently pay dividends.

What is ScandiDos AB’s EPS estimate?

ScandiDos AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ScandiDos AB have?

ScandiDos AB has 57,011,086 shares outstanding.

What happened to ScandiDos AB’s price movement after its last earnings report?

ScandiDos AB reported an EPS of kr0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.807%.

Which hedge fund is a major shareholder of ScandiDos AB?

Currently, no hedge funds are holding shares in SE:SDOS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ScandiDos AB

ScandiDos AB (publ), established in Uppsala, Sweden, in 2005, develops advanced measurement systems and software specifically for the quality assurance (QA) and validation demands of innovative medical treatments utilized in clinics worldwide. Their flagship Delta4 Family solution offers comprehensive dose verification, both before and during treatment, across a wide array of radiation therapy techniques, including VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy. The Delta4 Discover is a transmission detector providing real-time measurements to bolster confidence and patient safety. Additionally, the Delta4 Phantom+ system ensures accurate verification of IMRT, VMAT, and TomoTherapy plans. The company's product line also includes HexaMotion, a dedicated solution for motion management. Their software offerings comprise Delta4DVH Anatomy, which verifies and analyzes the administered dose within a patient's anatomical structures, and Delta4 Machine QA, designed for conducting quality checks on machine rotation, start-up performance, and dynamic beam modulation.